Koichi Mitsuya

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers

Epithelial–mesenchymal transition: a new target in anticancer drug discovery

On-tissue spatially resolved glycoproteomics guided by N-glycan imaging reveal global dysregulation of canine glioma glycoproteomic landscape

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Tumor Associated Macrophages, as the Dominant Immune Cells, Are an Indispensable Target for Immunologically Cold Tumor—Glioma Therapy?

Engineering challenges for brain tumor immunotherapy

Macrophages in immunoregulation and therapeutics

Cancer immunotherapy via dendritic cells

Trial watch

EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: A case–control study of overall survival

Delivery technologies for cancer immunotherapy

Lung cancer: current therapies and new targeted treatments

Inflammation and tumor progression: signaling pathways and targeted intervention

The JAK/STAT signaling pathway: from bench to clinic

The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer

The Microenvironmental Landscape of Brain Tumors

Immunosuppressive mechanisms in glioblastoma: Fig. 1.

Traumatic spinal cord injury

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors

Management of glioblastoma: State of the art and future directions

Epithelial Mesenchymal Transition in Tumor Metastasis

EMT, CSCs, and drug resistance: the mechanistic link and clinical implications

Prevalence of non-traumatic spinal cord injury in Victoria, Australia

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

Emerging roles for the IL-6 family of cytokines in pancreatic cancer

The Tumor Microenvironment Innately Modulates Cancer Progression

Glycosylation Changes in Brain Cancer

Novel cancer-testis antigen expression on glioma cell lines derived from high-grade glioma patients

Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line

Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up

Immunological effects of the anti-programmed death-1 antibody on human peripheral blood mononuclear cells

The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line

Metastatic skull tumors: MRI features and a new conventional classification

α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial

Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure

Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status

Elevated preoperative neutrophil-to-lymphocyte ratio as a predictor of worse survival after resection in patients with brain metastasis